Victorian Rad Onc 2020/2021/2022 cohort at RANZCR annual ceremony #RANZCR2022 @RANZCRcollege @FacRadOncology @PeterMacRadOnc @AlfredHealth @ONJCancerCentre

After ADT for #ProstateCancer, how long does it take to recover testosterone? MARCAP meta-analysis ▶️ ~6 months to non-castrate T (regardless of 6 or 18 months ADT) ▶️ takes longer for non-hypogonadal T, and duration of ADT matters @weeloonong #ASTRO25 @ASTRO_org

Had a great dinner at @PalmCourtHotel with @DrPatCheung @weeloonong @theresekang_ RubenDelCastillo Great catching up and spending time at #ASTRO25

And also an educational session (Edu 05, right after CT session) on dose/ADT and endpoints with insight from multiple thought leaders based on work from MARCAP @DrSpratticus @weeloonong @angela_jia_ @MartinMaMDPhD

Not possible without the collaboration between @NRGonc and @TROGFightCancer, support from @KHoffmanMD @DrPaulNguyen and contributions of the many Australian CI @jeremymillar @theresekang_ @Niluja5 @DavePryorRO @damien_bolton and many others not on X! 🙏🙏

honoured to have @DrAndrewLoblaw as Visiting Professor at @AlfredHealth @MonashSTM - 🙏 for spending the day with our trainees, supporting the introduction of transperineal prostate fiducials insertion under LA in our department, attending peer review/ chart round and GU MDT.

@VedangMurthy group published on bowel bag dosimetric predictors / limits for acute toxicity for pelvic/prostate SBRT https://t.co/cN95ruqhxk Please now see @weeloonong article on predictors / suggested OAR limits for late outcomes: https://t.co/fTQIcMmVEd

Please join our esteemed international RO speakers in Melbourne in October for #RANZCR2025! Early bird registrations close 15 July 2025. https://t.co/LDUzn6gU2Q @RANZCRcollege @NiuSanford @reshmajagsi @SahgalArjun @AmarUKishan @SimonLo21054188 @jmmrad @BoekeSimon @GkikaEleni2

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a phase 3 https://t.co/tBNJGPjKO5 Authors: @alison_tree, @nickva1, & @EmmaHall71 @royalmarsden, @Accuray, @ICR_London

New review led by @DeepOnco of @royalmarsdenNHS outlines global trends and evolving diagnostics, treatment, and surveillance of #ProstateCancer. Read: https://t.co/AUAGW1mzrM @PCaParker @AmarUKishan @VedangMurthy @nickva1 @alison_tree @APCCC_Lugano @ICR_London

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

@weeloonong leads pub in @EurUrolOncol for #PATRIOT (#SBRT weekly vs every other day treatment for favourable risk #prostatecancer ) No stat diff in bioc fail (mFU of 91mo) Planning to combine with @ZilliThomas #NOVALIS study (same design) free link👉 https://t.co/Bq1vHzBUpI

As #RANZCR2024 comes to a close, it is my honour to be the RO convenor for #RANZCR2025, with a line-up of esteemed international speakers (more TBC). Please save the date, and see you in Melbourne 23-25 October 2025! @AmarUKishan @SahgalArjun @NiuSanford @fabiomoraesmd

excited that we are now offering prostate SABR at @BarwonHealth Andrew Love Cancer Center, benefiting men with prostate cancer in western regional Victoria! @VicGovDH @TargetingCancer

Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! https://t.co/9ja6OZFRab @alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa

In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: https://t.co/mYGY3Zd2MX

After 4 years of the GÖTEBORG-2 trial, MRI-targeted biopsy led to less detection of clinically insignificant prostate cancer than systematic biopsy without compromising the detection of cancer that may affect survival. Read the full trial results: https://t.co/qJVOg3gmIj

🙏Thanks to mentoring by @AmarUKishan , stats support by Tahmineh Romero, and contributions by coauthors 🙏 Thanks to funding from RANZCR-TROG research grant @RANZCRcollege @TROGfightcancer 🙏Thanks to patients from multiple trials who contributed data for the analysis

Thomas Kennedy leads 10y prostate #SBRT outcomes from 3 different prospective studies now epub at #RedJ @IJROBP https://t.co/3mOtqEntxv Great biochemical control to 15 years and only 1% chance of mets! Note 10% of UIR pts received ADT and none had whole pelvic RT (-> #PR24)

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦@DrTolan⁩ @alison_tree⁩ ⁦@cpeedell⁩ @DrAndrewLoblaw⁩ ⁦@EmmaHall71⁩ @ProfJOSullivan⁩ https://t.co/HlFxb3jegQ

Online First: #Palliative #radiotherapy versus best supportive care in patients with painful #hepaticcancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study #radonc https://t.co/BYHtpmo9SO